

FIG. 1

Shared HLA Antigens






FIG. 2


J13




L889




L993



L913








L933



- 62 □ 64 ■ 104
- 111 □ 113 □ 116
- SIVgag □ Inactivated Virus


• Arrows at weeks 4 and 8 represent time of boosting with peptides in IFA.
 • Arrows at weeks 22, 24, and 25 represent time of boosting with peptide-pulsed autologous dendritic cells.
 • Arrow at week 29 represents time of challenge with SHIV-KU2.

FIG. 3



- The NK-activity was shown for an E:T ratio of 50:1.
- The arrow indicates challenge with SHIV-KU2 at week 29 post-immunization.

FIG. 4



- The arrow indicates challenge with SHIV-KD2 at week 29 post-immunization.
- The circles indicate CD4 cells while the squares indicate CD8 cells.

FIG. 5

FIG. 6

HIV envelope-specific CTL activity in control and peptide-vaccinated monkeys




FIG. 7A

Peptide-specific proliferative responses prior to DC infusions
in vaccinated and control monkeys




FIG. 7B

Peptide-specific proliferative responses after DC infusion in vaccinated and control monkeys




FIG. 8

Post-challenge analyses of blood samples from control and vaccinated monkeys




FIG. 9

Changes in total body weights in
control and peptide-vaccinated monkeys
after SHIV-ku2 challenge




FIG. 10




FIG. 11




FIG. 12A




FIG. 12B





FIG. 13A



;




FIG. 13C

pG-CMVI-#63




FIG. 13D





FIG. 13E



11

